INTI
Inhibitor Therapeutics, Inc. [INTI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
INTI Stock Summary
In the News
INTI Financial details
Company Rating
-
Market Cap
13.33M
Income
-2.94M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
0.75
Forward P/E
-
PEG
-0.05
P/S
-
P/B
2.73
P/C
-
P/FCF
1.78
Quick Ratio
60.97
Current Ratio
61.41
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.02
EPS next Y
-
EPS next Q
-
EPS this Y
-154.15%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
74.36%
-
-
-
-
SMA20
16.67%
SMA50
-
SMA100
-12.5%
Inst Own
-
Inst Trans
-
ROA
244%
ROE
316%
ROC
-0.27%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.013-0.3
52W High
-
52W Low
-
RSI
53.73
Rel Volume
5.55
Avg Volume
9K
Volume
50K
Perf Week
1.54%
Perf Month
10%
Perf Quarter
17.65%
Perf Half Y
4.38%
-
-
-
-
Beta
-0.768
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.066
Change
0%
Company Profile
- Volume Average 9K
- Market Capitalization 13.33M
- Employee 3
- CEO Dr. Francis E. O'Donnell Jr., M.D.
- Headquarters Tampa,FL,US
- IPO Date 2013-09-13
-
Website
https://www.inhibitortx.com 
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
